Cost-effectiveness analysis of tocilizumab in combination with methotrexate for rheumatoid arthritis: a Markov model based on data from Serbia, country in socioeconomic transition

Kostic M, Jovanovic S, Tomovic M, Milenkovic MP, Jankovic SM

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
24665571

Indexing Status
Subject indexing assigned by NLM

MeSH
Antibodies, Monoclonal, Humanized /economics /therapeutic use; Antirheumatic Agents /economics /therapeutic use; Arthritis, Rheumatoid /drug therapy; Cost-Benefit Analysis; Drug Therapy, Combination; Humans; Markov Chains; Methotrexate /economics /therapeutic use; Serbia; Socioeconomic Factors

AccessionNumber
22014012914

Date bibliographic record published
29/08/2014